Thursday, July 30, 2026
EU authorizes Pfizer-BioNTech's updated XFG COVID vaccine
The European Commission granted marketing authorization on July 29 for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant, for use in people 6 months and older. The approval followed a positive recommendation from the EMA's Committee for Medicinal Products for Human Use on July 23, and shipments to EU member states were expected to begin shortly to prepare for the fall vaccination season.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- BioNTech halts Phase 2 colorectal cancer vaccine trialFriday, September 4, 2026
- BioNTech, Genentech halt mRNA colorectal cancer vaccine trialSaturday, August 29, 2026
- FDA approves Pfizer-BioNTech's XFG-adapted COVID vaccineFriday, August 28, 2026
- BioNTech cuts 2026 revenue guidance as COVID sales fadeSunday, August 23, 2026